Preparing for Scan Day

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

From a personalized melanoma vaccine to new options for biliary, stomach, lung and endometrial cancers, here are 5 ESMO 2026 abstracts to watch.

Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.

The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.

In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.

The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.

The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.